SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will ...

Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6. The asset ...

The cheerful Mr. Fun Computer is gone, replaced by a digital ghost corrupted by a virus from Black. Now he's infecting everything—spreading sorrow, erasing joy, and enslaving his former allies. With ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...

Google on Tuesday announced a brand-new AI model called Gemini 2.5 Computer Use, releasing it in preview to developers. If you've been following the AI industry, you might be familiar with the term ...

Google is now letting developers preview the Gemini 2.5 Computer Use model behind Project Mariner and agentic features in AI Mode. This “specialized model” can interact with graphical user interfaces, ...

What if your PC case could fold flat, pack up like a briefcase, and still turn heads with its minimalist design? Enter Teenage Engineering’s “Computer-2,” a bold reimagining of what a compact ...

INKmune effectively primes resting NK cells into tumor-killing memory-like NK cells, showing a favorable safety profile across all dose levels in mCRPC patients. The trial demonstrated significant ...

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists. Jay Chhablani, MD, Vice Chair at the University of ...

Krystal Biotech, Inc. announced the dosing of the first patient in its Phase 1/2 clinical trial, EMERALD-1, which is evaluating KB801, an eye drop gene therapy for neurotrophic keratitis (NK), a rare ...